ingenol mebutate：癌症免疫疗法进一步发展的潜力。
Ingenol mebutate: potential for further development of cancer immunotherapy.
作者信息
Doan Hung Q, Gulati Nicholas, Levis William R
机构信息
School of Medicine, University of Texas Medical Branch, Galveston, TX, USA.
出版信息
J Drugs Dermatol. 2012 Oct;11(10):1156-7.
Ingenol mebutate is a diterpene ester derived from the plant Euphorbia peplus and is FDA approved for the topical treatment of actinic keratoses (AK). Shown to be efficacious with as little as a 3-day trial, this compound is being further tested for the topical treatment of other nonmelanoma skin cancers with promising preclinical data. In an effort to elucidate the molecular mechanism of this novel drug, Stahlhut et al. (2012) suggest a role for calcium and apoptosis. Further studies are needed to evaluate the intracellular mechanisms of ingenol mebutate-mediated cytotoxicity. Additionally, studies such as this not only shed light on the mechanism of ingenol mebutate and its derivatives, but also pave the way for evaluating the involvement of the immune system in eliminating drug-treated cells and tissues. This has important implications for the development of novel topical immune modulatory products and the field of topical immunotherapy.
ingenol mebutate是一种从大戟属植物中提取的二萜酯，已获美国食品药品监督管理局（FDA）批准用于光化性角化病（AK）的局部治疗。该化合物在仅为期3天的试验中就显示出有效性，目前正基于有前景的临床前数据，进一步测试其用于其他非黑色素瘤皮肤癌的局部治疗。为了阐明这种新药的分子机制，Stahlhut等人（2012年）提出钙和细胞凋亡可能发挥作用。需要进一步研究来评估ingenol mebutate介导的细胞毒性的细胞内机制。此外，此类研究不仅有助于揭示ingenol mebutate及其衍生物的作用机制，还为评估免疫系统在清除经药物处理的细胞和组织中的作用铺平了道路。这对于新型局部免疫调节产品的开发以及局部免疫治疗领域具有重要意义。
Zotero 插件